CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP) announced participation at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, at 9:30 a.m. ET. Senior management will represent the company, which specializes in gene-based medicines for severe diseases using its CRISPR/Cas9 technology. A live webcast will be available on the company’s website, with a replay accessible for 14 days post-event. CRISPR Therapeutics holds collaborations with Bayer, Vertex Pharmaceuticals, and ViaCyte, and operates headquarters in Zug, Switzerland, and a U.S. subsidiary in Cambridge, Massachusetts.
- None.
- None.
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.
A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
reides@wcgworld.com
FAQ
What event will CRISPR Therapeutics participate in on December 2, 2020?
What time is CRISPR Therapeutics' presentation at the Piper Sandler Conference?
Where can I watch the CRISPR Therapeutics conference presentation live?
How long will the CRISPR Therapeutics presentation replay be available?
What is the focus of CRISPR Therapeutics' business?
